Related Experiment Video
Updated: Dec 16, 2025
13:04
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
24.6K
Hepatitis c virus and chronic kidney disease
Muhammad Umair Khan1, Mohamed Ibrahim Mahmoud1, Adeel A Butt2,3
1Department of Medicine, Division of Gastroenterology, Hamad Medical Corporation , Doha, Qatar.
Expert Review of Gastroenterology & Hepatology
|July 3, 2020
Summary
Direct acting antiviral agents (DAAs) effectively treat Hepatitis C virus (HCV) infection, achieving high viral eradication rates. These treatments are safe and well-tolerated in patients with chronic kidney disease (CKD) and those who have undergone renal transplantation.
Area of Science:
- Nephrology
- Hepatology
- Virology
Background:
- Hepatitis C virus (HCV) infection is linked to increased chronic kidney disease (CKD) incidence, progression, and mortality in CKD and renal transplant patients.
- Direct acting antiviral agents (DAAs) have transformed HCV treatment, achieving high viral eradication rates.
- DAAs demonstrate excellent safety and tolerability in CKD and renal transplant populations.
Purpose of the Study:
- To review the association between HCV and CKD incidence, progression, and patient outcomes.
- To discuss HCV treatment options for patients with CKD, renal transplants, and HCV-associated glomerular disease.
Main Methods:
- Literature review focusing on HCV, CKD, renal transplantation, and DAA therapies.
- Analysis of treatment outcomes, safety, and tolerability of DAAs in specific patient cohorts.
Main Results:
- DAAs achieve 90-100% viral eradication in treated patients, including those with advanced CKD and on dialysis.
- DAAs are safe and effective in renal transplant recipients.
- HCV-infected grafts can be utilized with successful post-transplant viral eradication.
Conclusions:
- DAAs represent a revolutionary advancement for treating HCV in patients with advanced CKD and end-stage renal disease.
- The efficacy, safety, and tolerability of DAAs facilitate HCV treatment in both dialysis and renal transplant patients.
- DAA therapy enables successful management of HCV in renal transplant recipients, including those receiving HCV-viremic grafts.
Related Concept Videos
01:25Chronic Kidney Disease I: Introduction
442
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
442
01:24Chronic Kidney Disease II: Clinical Manifestations
442
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
442
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
111
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
111
01:28Chronic Kidney Disease III: Interprofessional Care
256
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
256
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
139
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
139
01:29Acute Kidney Injury II: Pathophysiology
699
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
699